Haemonetics Corporation (FRA:HAZ)

Haemonetics Statistics

Total Valuation

Haemonetics has a market cap or net worth of EUR 3.26 billion. The enterprise value is 4.06 billion.

Market Cap	3.26B
Enterprise Value	4.06B

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	46.81M
Shares Outstanding	n/a
Shares Change (YoY)	-4.63%
Shares Change (QoQ)	-1.42%
Owned by Insiders (%)	1.19%
Owned by Institutions (%)	111.58%
Float	46.22M

Valuation Ratios

The trailing PE ratio is 22.66 and the forward PE ratio is 15.40.

PE Ratio	22.66
Forward PE	15.40
PS Ratio	2.87
PB Ratio	4.49
P/TBV Ratio	n/a
P/FCF Ratio	16.31
P/OCF Ratio	13.19
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 13.09, with an EV/FCF ratio of 20.31.

EV / Earnings	28.21
EV / Sales	3.55
EV / EBITDA	13.09
EV / EBIT	18.66
EV / FCF	20.31

Financial Position

The company has a current ratio of 1.64, with a Debt / Equity ratio of 1.44.

Current Ratio	1.64
Quick Ratio	0.92
Debt / Equity	1.44
Debt / EBITDA	3.40
Debt / FCF	5.24
Interest Coverage	5.36

Financial Efficiency

Return on equity (ROE) is 19.47% and return on invested capital (ROIC) is 7.40%.

Return on Equity (ROE)	19.47%
Return on Assets (ROA)	6.36%
Return on Invested Capital (ROIC)	7.40%
Return on Capital Employed (ROCE)	13.35%
Revenue Per Employee	375,646
Profits Per Employee	47,581
Employee Count	3,023
Asset Turnover	0.53
Inventory Turnover	1.50

Taxes

In the past 12 months, Haemonetics has paid 41.83 million in taxes.

Income Tax	41.83M
Effective Tax Rate	22.53%

Stock Price Statistics

The stock price has decreased by -15.85% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-15.85%
50-Day Moving Average	49.94
200-Day Moving Average	54.81
Relative Strength Index (RSI)	83.09
Average Volume (20 Days)	10

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.07

Income Statement

In the last 12 months, Haemonetics had revenue of EUR 1.14 billion and earned 143.84 million in profits. Earnings per share was 2.94.

Revenue	1.14B
Gross Profit	675.63M
Operating Income	216.17M
Pretax Income	185.67M
Net Income	143.84M
EBITDA	308.14M
EBIT	216.17M
Earnings Per Share (EPS)	2.94

Balance Sheet

The company has 254.05 million in cash and 1.05 billion in debt, giving a net cash position of -793.70 million.

Cash & Cash Equivalents	254.05M
Total Debt	1.05B
Net Cash	-793.70M
Net Cash Per Share	n/a
Equity (Book Value)	726.21M
Book Value Per Share	15.53
Working Capital	300.49M

Cash Flow

In the last 12 months, operating cash flow was 247.19 million and capital expenditures -47.34 million, giving a free cash flow of 199.85 million.

Operating Cash Flow	247.19M
Capital Expenditures	-47.34M
Free Cash Flow	199.85M
FCF Per Share	n/a

Margins

Gross margin is 59.50%, with operating and profit margins of 19.04% and 12.67%.

Gross Margin	59.50%
Operating Margin	19.04%
Pretax Margin	16.35%
Profit Margin	12.67%
EBITDA Margin	27.14%
EBIT Margin	19.04%
FCF Margin	17.60%

Dividends & Yields

Haemonetics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	4.63%
Shareholder Yield	4.63%
Earnings Yield	4.41%
FCF Yield	6.13%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on December 3, 2012. It was a forward split with a ratio of 2.

Last Split Date	Dec 3, 2012
Split Type	Forward
Split Ratio	2

Scores

Haemonetics has an Altman Z-Score of 2.55 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.55
Piotroski F-Score	6